Showing 2001-2010 of 2314 results for "".
- EyeYon Medical Raises $25 million in Series C to Transform Corneal Carehttps://modernod.com/news/eyeyon-medical-raises-25-million-in-series-c-to-transform-corneal-care/2478969/EyeYon Medical announced the completion of a $25 million in a Series C funding, which will be used to expand the clinical trials of EyeYon Medical’s flagship product, EndoArt. EndoArt is the first synthetic implant that enables doctors to treat chronic corneal edema with a minimally invasi
- J&J’s Coronavirus Vaccine Garners WHO Emergency-Use Listinghttps://modernod.com/news/jjs-coronavirus-vaccine-garners-who-emergency-use-listing/2478968/Johnson & Johnson said that the World Health Organization (WHO) has issued an emergency-use listing for its single-dose coronavirus vaccine Ad26.COV2.S to prevent COVID-19 in people 18 years and older. Chief scientific officer Paul Stoffels stated that “achieving this important prerequi
- EU Greenlights J&J’s Coronavirus Vaccinehttps://modernod.com/news/eu-greenlights-jjs-coronavirus-vaccine/2478966/The European Commission granted a conditional marketing authorization for Johnson & Johnson’s single-dose COVID-19 vaccine Ad26.COV2.S in people 18 years of age and over. The decision comes just hours after the European Medicines Agency (EMA) gave its backing following a review of ̶
- J&J’s COVID-19 Vaccine Wins FDA Authorization for Emergency Usehttps://modernod.com/news/jjs-covid-19-vaccine-wins-fda-authorization-for-emergency-use/2478921/The US has added a third option to its arsenal of COVID-19 vaccines after the FDA authorized Johnson & Johnson’s single-dose candidate Ad26.COV2.S for emergency use in people 18 years and older on Saturday. Peter Marks, director of the FDA’s Center for Biologics Evaluation a
- Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopiahttps://modernod.com/news/ocuphire-initiates-enrollment-in-vega-1-phase-2-trial-investigating-nyxol-in-presbyopia/2478887/Ocuphire Pharma announced that it has enrolled the first patients in a phase 2 proof of concept trial, titled VEGA-1, to evaluate a combination kit of Nyxol and low-dose pilocarpine in presbyopia. Over 12 sites representing a majority of the planned clinical sites are activated and recruiting pat
- Real-World Use Analysis Backs Efficacy of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/real-world-use-analysis-backs-efficacy-of-pfizer-biontechs-covid-19-vaccine/2478875/Results from real-world use of Pfizer and BioNTech’s BNT162b2 show that two doses of the mRNA-based vaccine can cut the number of symptomatic COVID-19 infections by 94%, whilst also reducing severe illness by 92%. The Clalit Research Institute’s preliminary findings come from an analy
- GenSight Biologics Announces Publication of Results from Lumevoq Phase 1/2a Clinical Trial REVEAL in BioDrugshttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-phase-1-2a-clinical-trial-reveal-in-biodrugs/2478868/GenSight Biologics announced that the journal BioDrugs has published results from REVEAL, the phase 1/2a clinical trial that evaluated the safety of Lumevoq gene therapy in subjects with ND4 Leber Hereditary Optic Neuropathy (LHON) and determined the dose subsequently used in the ph
- Insurer Ducks Virus Coverage Claims From NJ Eye Practicehttps://modernod.com/news/insurer-ducks-virus-coverage-claims-from-nj-eye-practice/2478857/A proposed class action lawsuit from an eye clinic in New Jersey, which was seeking to recoup losses it incurred during the COVID-19 pandemic from an insurance company, was struck down by a New Jersey federal judge, according to a LAW360
- Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry AMD in Patients with High-Risk Genetic Variantshttps://modernod.com/news/gemini-therapeutics-completes-enrollment-in-phase-2a-trial-of-gem103-in-dry-amd-in-patients-with-high-risk-genetic-variants/2478851/Gemini Therapeutics announced the completion of enrollment in its phase 2a “ReGAtta” study. ReGAtta is a dose escalation trial of GEM103, a recombinant human complement factor H (CFH), in dry AMD patients with CFH loss-of-function gene variants. The trial is designed to evaluate safet
- Medicom Healthcare Signs Asset Purchase Agreement of Bimatoprost 0.3 mg/mL, 3mlhttps://modernod.com/news/medicom-healthcare-signs-asset-purchase-agreement-of-bimatoprost-0-3-mg-ml-3ml/2478852/Medicom Healthcare and Famar Health Care Services Madrid have announced the signing of an Asset Purchase Agreement (APA) for the acquisition by Medicom of the pharmaceutical dossier of Bimatorost 0.3 mg/mL, 3ml, preservative free eye drop solution, developed by Famar R&D. Under this agreement